Effects of BAY 41-2272, an activator of nitric oxide-independent site of soluble guanylate cyclase, on human NADPH oxidase system from THP-1 cells

European Journal of Pharmacology

Volumn 567, Issue 1-2, 2007, Pages 43-49

  Borges de Oliveira Junior, Edgar ^a   Thomazzi, Sara Maria ^b   Rehder, Jussara ^a   Antunes, Edson ^a   Condino Neto, Antonio ^a,c  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b FEDERAL UNIVERSITY OF SERGIPE   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

BAY 41 2272; cAMP; cGMP; gp91phox; Human macrophage; Myeloid cell; NADPH oxidase; Phagocyte

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; 9 (TETRAHYDRO 2 FURYL)ADENINE; ADENYLATE CYCLASE INHIBITOR; CYCLIC AMP; CYCLIC GMP; GLYCOPROTEIN GP 91; GUANYLATE CYCLASE ACTIVATOR; GUANYLATE CYCLASE INHIBITOR; ISOBUTYLMETHYLXANTHINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; OXYGEN; PHOSPHODIESTERASE INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; ZAPRINAST;

ARTICLE; CELL LEVEL; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MYELOMONOCYTIC LEUKEMIA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

CELL LINE; CELL SURVIVAL; CYCLIC AMP; CYCLIC GMP; ENZYME ACTIVATION; GUANYLATE CYCLASE; HUMANS; MEMBRANE GLYCOPROTEINS; NADPH OXIDASE; NITRIC OXIDE; PYRAZOLES; PYRIDINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SUPEROXIDES;

EID: 34249033025     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.04.018     Document Type: Article

References (53)

1. Babior B.M. NADPH oxidase. Curr. Opin. Immunol. 16 (2004) 42-47
2. Barker K.A., Orkin S.H., and Newburger P.E. Expression of the X-CGD gene during induced differentiation of myeloid leukemia cell line HL-60. Mol. Cell. Biol. 8 (1988) 2804-2810
3. Batot G., Martel C., Capdeville N., Wientjes F., and Morel F. Characterization of neutrophil NADPH oxidase activity reconstituted in a cell-free assay using specific monoclonal antibodies raised against cytochrome b558. Eur. J. Biochem. 234 (1995) 208-215
4. Bawankule D.U., Sathishkumar K., Sardar K.K., Chanda D., Krishna A.V., Prakash V.R., and Mishra S.K. BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-4-ylamine]-induced dilation in ovine pulmonary artery: role of sodium pump. J. Pharmacol. Exp. Ther. 314 (2005) 207-213
5. Becker E.M., Alonso-Alija C., Apeler H., Gerzer R., Minuth T., Plei U., Schmidt P., Schramm M., Schroder H., Schroeder W., Steinke W., Straub A., and Stasch J.P. NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272. BMC Pharmacol. 1 (2001) 13-24
6. Bei L., Lu Y., and Eklund E.A. HOXA9 activates transcription of the gene encoding gp91Phox during myeloid differentiation. J. Biol. Chem. 280 (2005) 12359-12370
7. Berger C.E., Horrocks B.R., and Datta H.K. cAMP-dependent inhibition is dominant in regulating superoxide production in the bone-resorbing osteoclasts. J. Endocrinol. 158 (1998) 311-318
8. Boss G.R. cGMP-induced differentiation of the promyelocytic cell line HL-60. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 7174-7178
9. Brandes R.P., and Kreuzer J. Vascular NADPH oxidases: molecular mechanisms of activation. Cardiovasc. Res. 65 (2005) 16-27
10. Chaplinski T.J., and Niedel J.E. Cyclic nucleotide-induced maturation of human promyelocytic leukemia cells. J. Clin. Invest. 70 (1982) 953-964
11. Condino-Neto A., Muscara M.N., Grumach A.S., Carneiro-Sampaio M.M., and De Nucci G. Neutrophils and mononuclear cells from patients with chronic granulomatous disease release nitric oxide. Br. J. Clin. Pharmacol. 35 (1993) 485-490
12. Condino-Neto A., Muscara M.N., Bellinati-Pires R., Carneiro-Sampaio M.M., Brandão A.C., Grumach A.S., and De Nucci G. Effect of therapy with recombinant human interferon-gamma on the release of nitric oxide by neutrophils and mononuclear cells from patients with chronic granulomatous disease. J. Interferon Cytokine Res. 16 (1996) 357-364
13. Connelly L., Jacobs A.T., Palacios-Callender M., Moncada S., and Hobbs A.J. Macrophage endothelial nitric-oxide synthase autoregulates cellular activation and pro-inflammatory protein expression. J. Biol. Chem. 278 (2003) 26480-26487
14. DeCoursey T.E., Morgan D., and Cherny V.V. The voltage dependence of NADPH oxidase reveals why phagocytes need proton channels. Nature 422 (2003) 531-534
15. El-Benna J., Dang P.M., Gougerot-Pocidalo M.A., and Elbim C. Phagocyte NADPH oxidase: a multicomponent enzyme essential for host defenses. Arch. Immunol. Ther. Exp. 53 (2005) 199-206
16. Evgenov O.V., Pacher P., Schmidt P.M., Hasko G., Schmidt H.H., and Stasch J.P. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat. Rev. Drug Discov. 5 (2006) 755-768
17. Ezeamuzie C.I. Requirement of additional adenylate cyclase activation for the inhibition of human eosinophil degranulation by phosphodiesterase IV inhibitors. Eur. J. Pharmacol. 417 (2001) 11-18
18. Friebe A., and Koesling D. Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Mol. Pharmacol. 53 (1998) 123-127
19. Gallin E.K. Ion channels in leukocytes. Physiol. Rev. 71 (1991) 775-811
20. Hobbs A.J. Soluble guanylate cyclase: the forgotten sibling. Trends Pharmacol. Sci. 18 (1997) 484-491
21. Hobbs A.J., and Ignarro L.J. Nitric oxide-cyclic GMP signal transduction system. Methods Enzymol. 269 (1996) 134-148
22. Hobbs A.J., Higgs A., and Moncada S. Inhibition of nitric oxide synthase as a potential therapeutic target. Annu. Rev. Pharmacol. Toxicol. 39 (1999) 191-220
23. Hwang T.-L., Hung H.-W., Kao S.-H., Teng C.-M., Wu C.-C., and Cheng S.J.-S. Soluble guanylyl cyclase activator YC-1 inhibits human neutrophil functions through a cGMP-independent but cAMP-dependent pathway. Mol. Pharmacol. 64 (2003) 1419-1427
24. Klos A., Bank S., Gietz C., Bautsch W., Kohl J., Burg M., and Kretzschmar T. C3a receptor on dibutyryl-cAMP-differentiated U937 cells and human neutrophils: the human C3a receptor characterized by functional responses and 125I-C3a binding. Biochemistry 31 (1992) 11274-11282
25. Kurosawa M., Numazawa S., Tani Y., and Yoshida T. ERK signaling mediates the induction of inflammatory cytokines by bufalin in human monocytic cells. Am. J. Physiol., Cell Physiol. 278 (2000) C500-C508
26. Laskin D.L., Beavis A.J., Sirak A.A., O'Connell S.M., and Laskin J.D. Differentiation of U-937 histiocytic lymphoma cells towards mature neutrophilic granulocytes by dibutyryl cyclic adenosine-3′,5′-monophosphate. Cancer Res. 50 (1990) 20-25
27. 3 cells. Clin. Exp. Pharmacol. Physiol. 32 (2005) 1078-1087
28. Maxey K.M., Maddipati K.R., and Birkmeier J. Interference in immunoassay. J. Clin. Immunoass. 15 (1992) 116-120
29. McCord J.M., and Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J. Biol. Chem. 244 (1969) 6049-6055
30. Moncada S., Palmer R.M., and Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43 (1991) 109-142
31. Mülsch A., Bauersachs J., Schafer A., Stasch J.-P., Kast R., and Busse R. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br. J. Pharmacol. 120 (1997) 681-689
32. Muzaffar S., Shukla N., Angelini G., and Jeremy J.Y. Nitroaspirins and morpholinosydnonimine but not aspirin inhibit the formation of superoxide and the expression of gp91phox induced by endotoxin and cytokines in pig pulmonary artery vascular smooth muscle cells and endothelial cells. Circulation 110 (2004) 1140-1147
33. Muzaffar S., Shukla N., Lobo C., Angelini G.D., and Jeremy J.Y. Iloprost inhibits superoxide formation and gp91phox expression induced by the thromboxane A2 analogue U46619, 8-isoprostane F2alpha, prostaglandin F2alpha, cytokines and endotoxin in the pig pulmonary artery. Br. J. Pharmacol. 141 (2004) 488-496
34. Muzaffar S., Shukla N., Srivastava A., Angelini G.D., and Jeremy J.Y. Sildenafil citrate and sildenafil nitrate (NCX 911) are potent inhibitors of superoxide formation and gp91phox expression in porcine pulmonary artery endothelial cells. Br. J. Pharmacol. 146 (2005) 109-117
35. Olsson I.L., and Breitman T.R. Induction of differentiation of the human histiocytic lymphoma cell line U-937 by retinoic acid and cyclic adenosine 3′:5′-monophosphate-inducing agents. Cancer Res. 42 (1982) 3924-3927
36. Olsson I.L., Breitman T.R., and Gallo R.C. Priming of human myeloid leukemic cell lines HL-60 and U-937 with retinoic acid for differentiation effects of cyclic adenosine 3′:5′-monophosphate-inducing agents and a T-lymphocyte-derived differentiation factor. Cancer Res. 42 (1982) 3928-3933
37. Olsson I.L., Breitman T.R., Sarngadharan M.G., and Gallo R.C. Mechanisms for induction of differentiation in the human promyelocytic cell line HL-60. Haematol. Blood Transfus. 28 (1983) 384-385
38. Ottonello L., Morone M.P., Dapino P., and Dallegri F. Tumour necrosis factor alpha-induced oxidative burst in neutrophils adherent to fibronectin: effects of cyclic AMP-elevating agents. Br. J. Haematol. 91 (1995) 566-570
39. Pradelles P., and Grassi J. Enzyme immunoassays of adenosine cyclic 3′,5′-monophosphate and guanosine cyclic 3′,5′-monophosphate using acetylcholinesterase. Anal. Chem. 61 (1989) 447-453
40. Roman V., Dugas N., Abadie A., Amirand C., Zhao H., Dugas B., and Kolb J.P. Characterization of a constitutive type III nitric oxide synthase in human U937 monocytic cells: stimulation by soluble CD23. Immunology 91 (1997) 643-648
41. Segal A.W., Garcia R., Goldstone H., Cross A.R., and Jones O.T. Cytochrome b-245 of neutrophils is also present in human monocytes, macrophages and eosinophils. Biochem. J. 196 (1981) 363-367
42. Shami P.J., and Weinberg J.B. Differential effects of nitric oxide on erythroid and myeloid colony growth from CD34+human bone marrow cells. Blood 87 (1996) 977-982
43. Skalnik D.G. Transcriptional mechanisms regulating myeloid-specific genes. Gene 284 (2002) 1-21
44. Stasch J.-P., Becker E.M., Alonso-Alija C., Apeler H., Dembowsky K., Feurer A., Gerzer R., Minuth T., Perzborn E., Pleiss U., Schroder H., Schroeder W., Stahl E., Steinke W., Straub A., and Schramm M. NO-independent regulatory site on soluble guanylate cyclase. Nature 410 (2001) 212-215
45. Stasch J.-P., Alonso-Alija C., Apeler H., Dembowsky K., Feurer A., Minuth T., Perzborn E., Schramm M., and Straub A. Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Br. J. Pharmacol. 135 (2002) 333-343
46. Straub A., Stasch J.-P., Alonso-Alija C., Benet-Buchholz J., Ducke B., Feurer A., and Furstner C. NO-independent stimulators of soluble guanylate cyclase. Bioorg. Med. Chem. Lett. 11 (2001) 781-784
47. Sundstrom C., and Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int. J. Cancer 17 (1976) 565-577
48. Teixeira C.E., Priviero F.B.M., Todd Jr. J., and Webb R.C. Vasorelaxing effect of BAY 41-2272 in rat basilar artery. Involvement of cGMP-dependent and independent mechanisms. Hypertension 47 (2006) 596-602
49. Teixeira C.E., Priviero F.B.M., and Webb R.C. Molecular mechanisms underlying rat mesenteric artery vasorelaxation induced by the nitric oxide-independent soluble guanylyl cyclase stimulators BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine] and YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole]. J. Pharmacol. Exp. Ther. 317 (2006) 258-266
50. Thomazzi S.M., Moreira J., De Nucci G., and Antunes E. Inhibitory effects on human eosinophil chemotaxis in vitro by BAY 41-2272, an activator of nitric oxide-independent site of soluble guanylate cyclase. Biochem. Pharmacol. 69 (2005) 875-882
51. Tsuchiya S., Yamabe M., Yamaguchi Y., Kobayashi Y., Konno T., and Tada K. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int. J. Cancer 26 (1980) 171-176
52. Vanuffelen B.E., Van Der Zee J., De Koster B.M., Vansteveninck J., and Elferink J.G. Intracellular but not extracellular conversion of nitroxyl anion into nitric oxide leads to stimulation of human neutrophil migration. Biochem. J. 330 (1998) 719-722
53. Wang J.P., Chang L.C., Raung S.L., Hsu M.F., Huang L.J., and Kuo S.C. Inhibition of superoxide anion generation by YC-1 in rat neutrophils through cyclic GMP-dependent and -independent mechanisms. Biochem. Pharmacol. 63 (2002) 577-585